Tang Jia-Cheng, Liu Jing-Hua, Liu Xiao-Long, Liang Xiao, Cai Xiu-Jun
Jia-Cheng Tang, Jing-Hua Liu, Xiao-Long Liu, Xiao Liang, Xiu-Jun Cai, Key Lab of Surgery of Zhejiang Province, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou 310016, Zhejiang Province, China.
World J Gastroenterol. 2015 Oct 21;21(39):11127-40. doi: 10.3748/wjg.v21.i39.11127.
To elucidate the role of fibulin-5 (FBLN-5) as a suppressor of hepatocellular carcinoma (HCC) cell metastasis via integrin.
The expression of FBLN-5 was determined by immunohistochemistry in 140 HCC samples and matched normal tissues, and was further confirmed by RT-PCR and Western blot analyses in various cell lines. Recombinant FBLN-5 was expressed in Escherichia coli BL21(DE3), purified and used in cell attachment assays. Expression of a specific plasmid or a specific siRNA in HCC cells resulted in the overexpression or knockdown of FBLN-5, respectively. Further, the migration and invasion of HCC cells were investigated using the Boyden chamber and transwell assays. The concentration of secreted matrix metalloproteinase 7 (MMP-7) was determined using ELISA.
FBLN-5 expression was found to be downregulated in HCC. Its expression was significantly correlated with advanced tumor metastasis; this was indicative of poor 5-year overall survival. Recombinant full-length human FBLN-5 promoted the attachment of HCC cells via integrins: it inhibited HCC cell adhesion and migration to fibronectin in a concentration-dependent manner. It also inhibited HCC cell migration and invasion through an integrin-binding arginine-glycine-aspartic acid (RGD) motif by downregulating MMP-7.
These results suggest that lower FBLN-5 expression is an important indicator of poor survival and that FBLN-5 inhibits HCC motility via an integrin-dependent mechanism. RGD-dependent suppression of MMP-7 by FBLN-5 might contribute to the development of new therapeutic strategies for HCC.
阐明纤连蛋白-5(FBLN-5)通过整合素作为肝细胞癌(HCC)细胞转移抑制因子的作用。
采用免疫组织化学法检测140例HCC样本及配对正常组织中FBLN-5的表达,并通过RT-PCR和蛋白质印迹分析在多种细胞系中进一步验证。重组FBLN-5在大肠杆菌BL21(DE3)中表达、纯化并用于细胞黏附试验。在HCC细胞中表达特定质粒或特定小干扰RNA(siRNA)分别导致FBLN-5的过表达或敲低。此外,采用Boyden小室和Transwell试验研究HCC细胞的迁移和侵袭能力。采用酶联免疫吸附测定(ELISA)法测定分泌的基质金属蛋白酶7(MMP-7)的浓度。
发现FBLN-5在HCC中表达下调。其表达与肿瘤晚期转移显著相关,这表明5年总生存率较差。重组全长人FBLN-5通过整合素促进HCC细胞的黏附:它以浓度依赖的方式抑制HCC细胞与纤连蛋白的黏附及迁移。它还通过下调MMP-7,通过整合素结合的精氨酸-甘氨酸-天冬氨酸(RGD)基序抑制HCC细胞的迁移和侵袭。
这些结果表明,较低的FBLN-5表达是生存不良的重要指标,且FBLN-5通过整合素依赖机制抑制HCC的运动性。FBLN-5对MMP-7的RGD依赖抑制作用可能有助于开发新的HCC治疗策略。